| Business Summary | | Celsion
Corporation
develops
medical
treatment
systems
primarily
to
treat
breast
cancer
and
a
chronic
prostate
enlargement
condition,
common
in
older
males,
known
as
benign
prostatic
hyperplasia,
using
minimally
invasive
focused
heat
technology.
The
Company
has
also
been
working
with
Duke
University
on
the
development
of
heat-sensitive
liposome
compounds
for
use
in
the
delivery
of
chemotherapy
drugs
to
tumor
sites,
and
with
Memorial
Sloan-Kettering
Cancer
Center
on
the
development
of
heat-activated
gene
therapy
compounds. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Celsion
Corp.
is
a
biomedical
research
and
development
company
dedicated
to
creating
and
marketing
medical
treatment
systems
for
cancer,
benign
prostatic
hyperplasia
and
other
diseases
using
focused
heat
energy.
For
the
nine
months
ended
6/30/01,
revenue
fell
4%
to
$3
thousand.
Net
loss
rose
59%
to
$4.6
million.
Revenues
reflect
the
clinical
testing
of
new
equipment.
Loss
reflects
increased
engineering
and
staffing
expenditures. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Augustine Cheung, Ph.D., 53 Chairman,
CSO | $224K | Spencer Volk, 66 Pres,
CEO | 244K | Anthony Deasey, 51 CFO,
Sr. VP | -- | Daniel Reale Exec. VP, Pres of BPH Division | -- | John Mon, 48 VP,
Sec., Treasurer, Gen. Mang. | -- | Dollar amounts are as of 30-Sep-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|